Viral Infections Therapeutics
1. Agenerase patent expiration
Treatment: Treatment of hiv infection
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6730679 | GLAXOSMITHKLINE | Pharmaceutical formulations |
Nov, 2017
(8 years ago) | |
| US5723490 | GLAXOSMITHKLINE | THF-containing sulfonamide inhibitors of aspartyl protease |
Mar, 2015
(10 years ago) | |
| US5646180 | GLAXOSMITHKLINE | Treatment of the CNS effects of HIV |
Jul, 2014
(11 years ago) | |
| US5585397 | GLAXOSMITHKLINE | Sulfonamide inhibitors of aspartyl protease |
Dec, 2013
(12 years ago) | |
Drugs and Companies using AMPRENAVIR ingredient
Market Authorisation Date: 15 April, 1999
Dosage: CAPSULE; SOLUTION
More Information on Dosage
AGENERASE family patents
2. Apretude patent expiration
Treatment: NA
APRETUDE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(3 months from now) | |
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Feb, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12138264 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(5 years from now) | |
| US11224597 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 20 December, 2021
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
APRETUDE family patents
3. Aptivus patent
expiration
Treatment: Treatment of hiv-1 infection by the co-administration of tipranavir and ritonavir.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6147095 | BOEHRINGER INGELHEIM | Method for improving the pharmacokinetics of tipranavir |
Oct, 2019
(6 years ago) | |
| US6169181 | BOEHRINGER INGELHEIM | Compounds useful to treat retroviral infections |
May, 2014
(11 years ago) | |
|
US6169181 (Pediatric) | BOEHRINGER INGELHEIM | Compounds useful to treat retroviral infections |
Nov, 2014
(11 years ago) | |
|
US6147095 (Pediatric) | BOEHRINGER INGELHEIM | Method for improving the pharmacokinetics of tipranavir |
Apr, 2020
(5 years ago) | |
| US6231887 | BOEHRINGER INGELHEIM | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
Jul, 2018
(7 years ago) | |
| US5852195 | BOEHRINGER INGELHEIM | Pyranone compounds useful to treat retroviral infections |
Jun, 2019
(6 years ago) | |
|
US6231887 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
Jan, 2019
(6 years ago) | |
|
US5852195 (Pediatric) | BOEHRINGER INGELHEIM | Pyranone compounds useful to treat retroviral infections |
Dec, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Dec 23, 2011 |
Drugs and Companies using TIPRANAVIR ingredient
Market Authorisation Date: 23 June, 2008
Dosage: SOLUTION; CAPSULE
More Information on Dosage
APTIVUS family patents
4. Edurant patent expiration
Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive adult patients with hiv-1 rna less than or equal to 100,000 at the start of therapy
EDURANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101629 | JANSSEN PRODS | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug, 2022
(3 years ago) | |
| US7638522 | JANSSEN PRODS | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
Apr, 2023
(2 years ago) | |
| US6838464 | JANSSEN PRODS | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
Feb, 2021
(4 years ago) | |
| US7067522 | JANSSEN PRODS | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
Dec, 2019
(6 years ago) | |
| US8080551 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(2 years ago) | |
|
US7125879 (Pediatric) | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Oct, 2025
(2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
| M(M-223) | Feb 01, 2021 |
| New Patient Population(NPP) | Mar 15, 2027 |
| Pediatric Exclusivity(PED) | Sep 15, 2027 |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 15 September, 2026
Market Authorisation Date: 20 May, 2011
Dosage: TABLET
More Information on Dosage
EDURANT family patents
5. Emtriva patent expiration
Treatment: Treatment of hiv infection
EMTRIVA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5814639 (Pediatric) | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(9 years ago) | |
| US5814639 | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(10 years ago) | |
|
US6703396 (Pediatric) | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(4 years ago) | |
|
US6642245 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(4 years ago) | |
| US6642245 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(5 years ago) | |
| US6703396 | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(4 years ago) | |
| US5914331 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(8 years ago) | |
|
US5914331 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(8 years ago) | |
Drugs and Companies using EMTRICITABINE ingredient
Market Authorisation Date: 28 September, 2005
Dosage: SOLUTION; CAPSULE
How can I launch a generic of EMTRIVA before it's drug patent expiration?
More Information on Dosage
EMTRIVA family patents
6. Fuzeon patent expiration
Treatment: Treatment of hiv
FUZEON IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6133418 | ROCHE | Synthetic peptide inhibitors of HIV transmission |
Nov, 2014
(11 years ago) | |
| US6475491 | ROCHE | Treatment of HIV and other viral infections using combinatorial therapy |
Jun, 2015
(10 years ago) | |
| US5464933 | ROCHE | Synthetic peptide inhibitors of HIV transmission |
Jun, 2013
(12 years ago) | |
Drugs and Companies using ENFUVIRTIDE ingredient
Market Authorisation Date: 13 March, 2003
Dosage: INJECTABLE
More Information on Dosage
FUZEON family patents
7. Intelence patent expiration
Treatment: Treatment of hiv infection in combination with one or more additional hiv antiviral agents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7887845 | JANSSEN R AND D | Antiviral compositions |
Mar, 2019
(6 years ago) | |
|
US6878717 (Pediatric) | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
May, 2020
(5 years ago) | |
| US6878717 | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Nov, 2019
(6 years ago) | |
| US8003789 | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Nov, 2019
(6 years ago) | |
| US7037917 | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Dec, 2020
(5 years ago) | |
|
US7037917 (Pediatric) | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Jun, 2021
(4 years ago) | |
|
US8003789 (Pediatric) | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
May, 2020
(5 years ago) | |
|
US7887845 (Pediatric) | JANSSEN R AND D | Antiviral compositions |
Sep, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 18, 2013 |
| New Patient Population(NPP) | Mar 26, 2015 |
| Pediatric Exclusivity(PED) | Jan 16, 2022 |
Drugs and Companies using ETRAVIRINE ingredient
NCE-1 date: 16 January, 2021
Market Authorisation Date: 26 March, 2012
Dosage: TABLET
More Information on Dosage
INTELENCE family patents
8. Isentress patent expiration
Treatment: Treatment of hiv infection
ISENTRESS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169780 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(2 years ago) | |
| US7754731 | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(3 years from now) | |
| US8771733 | MSD SUB MERCK | Pharmaceutical composition containing an anti-nucleating agent |
Jun, 2030
(4 years from now) | |
| US8852632 | MSD SUB MERCK | Pharmaceutical formulation containing a release rate controlling composition |
Jan, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7217713 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(3 years ago) | |
| US7435734 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(3 years ago) | |
|
US7217713 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(2 years ago) | |
| US7169780 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(2 years ago) | |
|
US7435734 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(2 years ago) | |
|
US7169780 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(1 year, 9 months ago) | |
|
US7754731 (Pediatric) | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
| New Dosage Form(NDF) | Dec 20, 2016 |
| New Patient Population(NPP) | Nov 22, 2020 |
| M(M-114) | Mar 28, 2015 |
| New Dosing Schedule(D-167) | May 26, 2020 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 21 December, 2011
Dosage: TABLET, CHEWABLE; POWDER; TABLET
How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage
ISENTRESS family patents
9. Livtencity patent expiration
Treatment: Treating post-transplant cmv infection/disease refractory to ganciclovir, valganciclovir, cidofovir or foscarnet by administering 800 or 1200 mg maribavir 2x daily where patient is concomitantly expos...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12295940 | TAKEDA PHARMS USA | Viral inhibitors, the synthesis thereof, and intermediates thereto |
Oct, 2043
(17 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12447170 | TAKEDA PHARMS USA | NA |
Nov, 2042
(16 years from now) | |
| US12447169 | TAKEDA PHARMS USA | NA |
Oct, 2031
(5 years from now) | |
| US12433907 | TAKEDA PHARMS USA | NA |
Nov, 2042
(16 years from now) | |
| US12213989 | TAKEDA PHARMS USA | Use of maribavir in treatment regimens |
Nov, 2042
(16 years from now) | |
| US11684632 | TAKEDA PHARMS USA | Maribavir isomers, compositions, methods of making and methods of using |
Jan, 2032
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2026 |
| Orphan Drug Exclusivity(ODE-388) | Nov 23, 2028 |
Drugs and Companies using MARIBAVIR ingredient
NCE-1 date: 23 November, 2025
Market Authorisation Date: 23 November, 2021
Dosage: TABLET
More Information on Dosage
LIVTENCITY family patents
10. Olumiant patent expiration
Treatment: Treatment of adult patients with severe alopecia areata; Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical vent...
OLUMIANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8158616 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
May, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9737469 | ELI LILLY AND CO | Methods for treating hair loss disorders |
Nov, 2031
(5 years from now) | |
| US9089574 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
Nov, 2032
(6 years from now) | |
| US11045474 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections |
Nov, 2032
(6 years from now) | |
| US8420629 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Mar, 2029
(3 years from now) | |
| US11806555 | ELI LILLY AND CO | Methods for treating hair loss disorders |
Nov, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 31, 2023 |
| New Indication(I-891) | May 10, 2025 |
| New Indication(I-890) | Jun 13, 2025 |
Drugs and Companies using BARICITINIB ingredient
NCE-1 date: 31 May, 2022
Market Authorisation Date: 08 October, 2019
Dosage: TABLET
How can I launch a generic of OLUMIANT before it's drug patent expiration?
More Information on Dosage
OLUMIANT family patents
11. Pifeltro patent expiration
Treatment: For use in combination with other antiretroviral agents to treat hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current a...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8486975 | MSD MERCK CO | Non-nucleoside reverse transcriptase inhibitors |
Aug, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-827) | Sep 19, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2023 |
| New Patient Population(NPP) | Jan 27, 2025 |
Drugs and Companies using DORAVIRINE ingredient
NCE-1 date: 30 August, 2022
Market Authorisation Date: 30 August, 2018
Dosage: TABLET
More Information on Dosage
PIFELTRO family patents
12. Prevymis patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7196086 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(1 year, 7 months ago) | |
| US8513255 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(1 year, 7 months ago) | |
| USRE46791 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
Jan, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603384 | MERCK SHARP DOHME | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative |
Feb, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2022 |
| Orphan Drug Exclusivity(ODE-165) | Nov 08, 2024 |
| New Indication(I-916) | Jun 05, 2026 |
| New Dosing Schedule(D-189) | Aug 02, 2026 |
| New Product(NP) | Aug 30, 2027 |
| New Patient Population(NPP) | Aug 30, 2027 |
| ODE*(ODE*) | Jun 05, 2030 |
| Orphan Drug Exclusivity(ODE-423) | Jun 05, 2030 |
| Orphan Drug Exclusivity(ODE-495) | Aug 30, 2031 |
| Orphan Drug Exclusivity(ODE-497) | Aug 30, 2031 |
Drugs and Companies using LETERMOVIR ingredient
NCE-1 date: 08 November, 2021
Market Authorisation Date: 08 November, 2017
Dosage: TABLET; SOLUTION
More Information on Dosage
PREVYMIS family patents
13. Prevymis patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46791 | MSD | Substituted dihydroquinazolines |
Jan, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2022 |
| Orphan Drug Exclusivity(ODE-165) | Nov 08, 2024 |
| New Indication(I-916) | Jun 05, 2026 |
| New Dosing Schedule(D-189) | Aug 02, 2026 |
| New Product(NP) | Aug 30, 2027 |
| New Patient Population(NPP) | Aug 30, 2027 |
| ODE*(ODE*) | Jun 05, 2030 |
| Orphan Drug Exclusivity(ODE-423) | Jun 05, 2030 |
| Orphan Drug Exclusivity(ODE-495) | Aug 30, 2031 |
| Orphan Drug Exclusivity(ODE-497) | Aug 30, 2031 |
Drugs and Companies using LETERMOVIR ingredient
Market Authorisation Date: 30 August, 2024
Dosage: PELLETS
More Information on Dosage
PREVYMIS family patents
14. Rapivab patent expiration
Treatment: Treatment of acute uncomplicated influenza in patients 6 months and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6503745 | BIOCRYST | Cyclopentane and cyclopentene compounds and use for detecting influenza virus |
Nov, 2019
(6 years ago) | |
| US6562861 | BIOCRYST | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
Dec, 2023
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778997 | BIOCRYST | Antiviral treatments |
May, 2027
(1 year, 3 months from now) | |
| US10391075 | BIOCRYST | Antiviral treatments |
Feb, 2027
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Patient Population(NPP) | Sep 20, 2020 |
Drugs and Companies using PERAMIVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Dosage: SOLUTION
More Information on Dosage
RAPIVAB family patents
15. Rebetol patent expiration
Treatment: Method of using ribavirin in combination with pegylated interferon alpha-2b to treat patients with chronic hepatitis c; Method of using ribavirin in combination with intron a (interferon alpha-2 b rec...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6524570 | SCHERING | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
|
US6524570 (Pediatric) | SCHERING | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
| US6472373 | SCHERING | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep, 2017
(8 years ago) | |
| US6461605 | SCHERING | Continuous low-dose cytokine infusion therapy |
Nov, 2016
(9 years ago) | |
| US6177074 | SCHERING | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
| US6790837 | SCHERING | Ribavirin syrup formulations |
Apr, 2023
(2 years ago) | |
|
US6790837 (Pediatric) | SCHERING | Ribavirin syrup formulations |
Oct, 2023
(2 years ago) | |
|
US6461605 (Pediatric) | SCHERING | Continuous low-dose cytokine infusion therapy |
May, 2017
(8 years ago) | |
|
US6177074 (Pediatric) | SCHERING | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
|
US6172046 (Pediatric) | SCHERING | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar, 2018
(7 years ago) | |
| US6172046 | SCHERING | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep, 2017
(8 years ago) | |
|
US6472373 (Pediatric) | SCHERING | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar, 2018
(7 years ago) | |
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 29 July, 2003
Dosage: SOLUTION
How can I launch a generic of REBETOL before it's drug patent expiration?
More Information on Dosage
REBETOL family patents
16. Rebetol patent expiration
Treatment: Method of tx a pt suspected of having hepatitis c by admin, in combination, a conjugate comprising peg 12000 & interferon alfa-2b in an amt of from 0.5mcg/kg to 2mcg/kg, once weekly, and ribavirin; Me...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6177074 (Pediatric) | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
|
US6524570 (Pediatric) | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
| US6472373 | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep, 2017
(8 years ago) | |
| US6172046 | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep, 2017
(8 years ago) | |
| US6461605 | MERCK SHARP DOHME | Continuous low-dose cytokine infusion therapy |
Nov, 2016
(9 years ago) | |
|
US6172046 (Pediatric) | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar, 2018
(7 years ago) | |
| US6177074 | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
|
US6472373 (Pediatric) | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar, 2018
(7 years ago) | |
| US6524570 | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
|
US6461605 (Pediatric) | MERCK SHARP DOHME | Continuous low-dose cytokine infusion therapy |
May, 2017
(8 years ago) | |
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 03 June, 1998
Dosage: CAPSULE
How can I launch a generic of REBETOL before it's drug patent expiration?
More Information on Dosage
REBETOL family patents
17. Relenza patent expiration
Treatment: Prophylaxis of influenza
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5360817 | GLAXOSMITHKLINE | Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid and their use as antiviral agents |
Jul, 2013
(12 years ago) | |
| US6294572 | GLAXOSMITHKLINE | Crystalline N-acetyl neuraminic acid derivatives and process for their preparation |
Dec, 2014
(11 years ago) | |
| US5648379 | GLAXOSMITHKLINE | Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents |
Jul, 2014
(11 years ago) | |
Drugs and Companies using ZANAMIVIR ingredient
Market Authorisation Date: 26 July, 1999
Dosage: POWDER
More Information on Dosage
RELENZA family patents
18. Reyataz patent expiration
Treatment: Method for treating hiv-1 infection
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5849911 | BRISTOL MYERS SQUIBB | Antivirally active heterocyclic azahexane derivatives |
Jun, 2017
(8 years ago) | |
| US6087383 | BRISTOL MYERS SQUIBB | Bisulfate salt of HIV protease inhibitor |
Dec, 2018
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5849911 | BRISTOL MYERS SQUIBB | Antivirally active heterocyclic azahexane derivatives |
Jun, 2017
(8 years ago) | |
| US6087383 | BRISTOL MYERS SQUIBB | Bisulfate salt of HIV protease inhibitor |
Dec, 2018
(7 years ago) | |
|
US5849911 (Pediatric) | BRISTOL MYERS SQUIBB | Antivirally active heterocyclic azahexane derivatives |
Dec, 2017
(8 years ago) | |
|
US6087383 (Pediatric) | BRISTOL MYERS SQUIBB | Bisulfate salt of HIV protease inhibitor |
Jun, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-116) | Sep 30, 2011 |
| New Dosing Schedule(D-130) | Feb 04, 2014 |
| New Product(NP) | Jun 02, 2017 |
| New Patient Population(NPP) | Sep 24, 2018 |
| Pediatric Exclusivity(PED) | Mar 24, 2019 |
Drugs and Companies using ATAZANAVIR SULFATE ingredient
Market Authorisation Date: 20 June, 2003
Dosage: CAPSULE; POWDER
How can I launch a generic of REYATAZ before it's drug patent expiration?
More Information on Dosage
REYATAZ family patents
19. Rukobia patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8461333 | VIIV HLTHCARE | Salts of prodrugs of piperazine and substituted piperidine antiviral agents |
Feb, 2025
(10 months ago) | |
| US7745625 | VIIV HLTHCARE | Prodrugs of piperazine and substituted piperidine antiviral agents |
Nov, 2027
(1 year, 10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168615 | VIIV HLTHCARE | Prodrugs of piperazine and substituted piperidine antiviral agents |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 02, 2025 |
Drugs and Companies using FOSTEMSAVIR TROMETHAMINE ingredient
NCE-1 date: 02 July, 2024
Market Authorisation Date: 02 July, 2020
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
RUKOBIA family patents
20. Tamiflu patent expiration
Treatment: Treatment and prophylaxis of influenza
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5952375 | ROCHE | Compounds and methods for synthesis and therapy |
Feb, 2015
(10 years ago) | |
| US5763483 | ROCHE | Carbocyclic compounds |
Dec, 2016
(9 years ago) | |
| US5866601 | ROCHE | Carbocyclic compounds |
Feb, 2016
(9 years ago) | |
|
US5952375 (Pediatric) | ROCHE | Compounds and methods for synthesis and therapy |
Aug, 2015
(10 years ago) | |
|
US5763483 (Pediatric) | ROCHE | Carbocyclic compounds |
Jun, 2017
(8 years ago) | |
|
US5866601 (Pediatric) | ROCHE | Carbocyclic compounds |
Aug, 2016
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-90) | Feb 22, 2013 |
| New Patient Population(NPP) | Dec 21, 2015 |
| M(M-251) | Aug 02, 2022 |
Drugs and Companies using OSELTAMIVIR PHOSPHATE ingredient
Market Authorisation Date: 02 July, 2007
Dosage: CAPSULE; FOR SUSPENSION
How can I launch a generic of TAMIFLU before it's drug patent expiration?
More Information on Dosage
TAMIFLU family patents
21. Tivicay patent expiration
Treatment: NA
TIVICAY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(1 year, 8 months from now) | |
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8129385 (Pediatric) | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Apr, 2028
(2 years from now) | |
|
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-166) | Jul 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Indication(I-758) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 09 June, 2016
Dosage: TABLET
How can I launch a generic of TIVICAY before it's drug patent expiration?
More Information on Dosage
TIVICAY family patents
22. Veklury patent expiration
Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (birth to < 18 years of age weighing > 1.5 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9949994 | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Oct, 2035
(9 years from now) | |
| US11492353 | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Dec, 2031
(5 years from now) | |
| US8318682 | GILEAD SCIENCES INC | 1′substituted carba-nucleoside analogs for antiviral treatment |
Apr, 2029
(3 years from now) | |
| US8008264 | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Sep, 2029
(3 years from now) | |
| USRE46762 | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Apr, 2029
(3 years from now) | |
| US9724360 | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Oct, 2035
(9 years from now) | |
| US10065958 | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Sep, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11266681 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(12 years from now) | |
| US10675296 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(12 years from now) | |
|
US11903953 (Pediatric) | GILEAD SCIENCES INC | Remdesivir treatment methods |
Nov, 2041
(15 years from now) | |
|
US10675296 (Pediatric) | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jan, 2039
(13 years from now) | |
|
US11266681 (Pediatric) | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jan, 2039
(13 years from now) | |
| US10695361 | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(10 years from now) | |
| US11975012 | GILEAD SCIENCES INC | Remdesivir treatment methods |
May, 2041
(15 years from now) | |
| US11382926 | GILEAD SCIENCES INC | Methods for treating Arenaviridae and Coronaviridae virus infections |
Sep, 2036
(10 years from now) | |
| US11007208 | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(10 years from now) | |
| US11903953 | GILEAD SCIENCES INC | Remdesivir treatment methods |
May, 2041
(15 years from now) | |
| US11491169 | GILEAD SCIENCES INC | Remdesivir treatment methods |
May, 2041
(15 years from now) | |
| US11975017 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(12 years from now) | |
|
US11492353 (Pediatric) | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Jun, 2032
(6 years from now) | |
|
US11491169 (Pediatric) | GILEAD SCIENCES INC | Remdesivir treatment methods |
Nov, 2041
(15 years from now) | |
|
US11007208 (Pediatric) | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Mar, 2037
(11 years from now) | |
|
US11382926 (Pediatric) | GILEAD SCIENCES INC | Methods for treating Arenaviridae and Coronaviridae virus infections |
Mar, 2037
(11 years from now) | |
|
US9949994 (Pediatric) | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Apr, 2036
(10 years from now) | |
|
US8008264 (Pediatric) | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Mar, 2030
(4 years from now) | |
|
US8318682 (Pediatric) | GILEAD SCIENCES INC | 1′substituted carba-nucleoside analogs for antiviral treatment |
Oct, 2029
(3 years from now) | |
|
US10065958 (Pediatric) | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Mar, 2032
(6 years from now) | |
|
US10695361 (Pediatric) | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Mar, 2037
(11 years from now) | |
|
USRE46762 (Pediatric) | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Oct, 2029
(3 years from now) | |
|
US9724360 (Pediatric) | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Apr, 2036
(10 years from now) | |
|
US11975017 (Pediatric) | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jan, 2039
(13 years from now) | |
|
US11975012 (Pediatric) | GILEAD SCIENCES INC | Remdesivir treatment methods |
Nov, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-183) | Jan 21, 2025 |
| New Patient Population(NPP) | Apr 25, 2025 |
| New Chemical Entity Exclusivity(NCE) | Oct 22, 2025 |
| M(M-301) | Jul 13, 2026 |
| Pediatric Exclusivity(PED) | Jan 13, 2027 |
Drugs and Companies using REMDESIVIR ingredient
NCE-1 date: 13 January, 2026
Market Authorisation Date: 22 October, 2020
Dosage: SOLUTION; POWDER
More Information on Dosage
VEKLURY family patents
23. Vocabria patent expiration
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg
VOCABRIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Feb, 2031
(5 years from now) | |
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-273) | Jan 31, 2025 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR SODIUM ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Dosage: TABLET
More Information on Dosage
VOCABRIA family patents
24. Xofluza patent expiration
Treatment: Method for post-exposure prophylaxis of influenza
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8987441 | GENENTECH INC | Substituted polycyclic carbamoyl pyridone derivative prodrug |
Sep, 2031
(5 years from now) | |
| US10759814 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(11 years from now) | |
| US10392406 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10633397 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(10 years from now) | |
| US11306106 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(11 years from now) | |
| US11925648 | GENENTECH INC | Solid dosage form having excellent stability |
Apr, 2041
(15 years from now) | |
| US8927710 | GENENTECH INC | Substituted polycyclic carbamoylpyridone derivative |
May, 2031
(5 years from now) | |
| US9815835 | GENENTECH INC | Substituted polycyclic carbamolypyridone derivative |
Jun, 2030
(4 years from now) | |
| US11261198 | GENENTECH INC | Process for preparing substituted polycyclic pyridone derivative and crystal thereof |
Sep, 2038
(12 years from now) | |
| US12064438 | GENENTECH INC | Pharmaceutical preparation excellent in light stability and dissolution property |
Oct, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-811) | Oct 16, 2022 |
| New Chemical Entity Exclusivity(NCE) | Oct 24, 2023 |
| M(M-187) | Dec 19, 2027 |
Drugs and Companies using BALOXAVIR MARBOXIL ingredient
NCE-1 date: 24 October, 2022
Market Authorisation Date: 23 November, 2020
Dosage: FOR SUSPENSION; TABLET
How can I launch a generic of XOFLUZA before it's drug patent expiration?
More Information on Dosage
XOFLUZA family patents